Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
390
-
Total 13F shares, excl. options
-
111M
-
Shares change
-
-932K
-
Total reported value, excl. options
-
$21B
-
Value change
-
-$165M
-
Put/Call ratio
-
0.44
-
Number of buys
-
192
-
Number of sells
-
-157
-
Price
-
$188.81
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q3 2021
476 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2021.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 390 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 111M shares
of 132M outstanding shares and own 84.47% of the company stock.
Largest 10 shareholders include FMR LLC (17.8M shares), VANGUARD GROUP INC (10.6M shares), BAILLIE GIFFORD & CO (10.4M shares), BlackRock Inc. (8.92M shares), WELLINGTON MANAGEMENT GROUP LLP (7.37M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.87M shares), Dodge & Cox (5.37M shares), STATE STREET CORP (2.8M shares), JPMORGAN CHASE & CO (2.45M shares), and MORGAN STANLEY (1.88M shares).
This table shows the top 390 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.